Table 1 Baseline patient characteristics
| Â | n(%) |
|---|---|
No. of patients | 67 |
Median age, yrs (range) | 61 (34–79) |
Gender (male/female) | Â |
  Male | 39 (58.2%) |
  Female | 28 (41.8%) |
Performance Status | Â |
  0 | 37 (55.2%) |
  1-2 | 30 (44.8%) |
Primary tumor site | Â |
  Colon | 54 (80.6%) |
  Rectum | 13 (19.4%) |
Treatment regimen | Â |
  CTX + irinotecan/folfiri | 60 (89.5%) |
  CTX + FOLFOX4 | 6 (9.0%) |
  CTX alone | 1 (1.5%) |
Previous chemotherapy | Â |
  Irinotecan-based | 62 (92.5%) |
  Fluoropyrimidine-based | 67 (100%) |
  Oxaliplatin-based | 54 (80.6%) |
  Bevacizumab-based | 26 (38.8%) |
No. of previous cancer treatments for advanced disease | Â |
  One | 15 (22.4%) |
  Two | 28 (41.8%) |
  Three | 15 (22.4%) |
  More than three | 9 (13.4%) |
Cutaneous toxicity | Â |
  0 | 19 (32.8%) |
  1 | 19 (32.8%) |
  2–3 | 20 (34.5%) |
  Unknown | 9 |